Customer Education

Webinar: Characterization of sub-visible particles with Amnis® imaging flow cytometry

Webinar Title: Webinar: Characterization of sub-visible particles with Amnis® imaging flow cytometry

Date: Thursday, November 30, 2017

Time: 10:00 AM CST

Duration: 60 minutes



 What Does it Cover?

Multi-spectral imaging flow cytometry (MIFC) is an established analytical method for cellular analysis, however has only recently been evaluated for characterization of sub-visible particles in therapeutic formulations despite numerous favorable attributes including:

  • Simultaneous collection of bright-field, side-scatter, and fluorescent imagery
  • Sensitive detection of particles 100 nm-100 μm
  • High image quality using 20X-60X magnification objectives
  • 100% sampling efficiency using hydrodynamic focusing
  • Small sample volume requirement (20 μL)
  • Linear concentration range up to 100 million/mL
  • Wide flow cell (250 μm) minimizes clogs

Assorted case studies using MIFC for analysis of protein and vaccine formulations will be presented, with an emphasis on measurements and samples that pose challenges for current techniques- including detection of small and transparent particles, direct analysis of highly concentrated formulations, and fluorescence characterization of particle type, chemical composition, and heterogeneous interactions.
 

 Who Should Attend?

Anyone interested in learning more about the ImageStream imaging flow cytometer and Multi-spectral imaging Flow cytometry (MIFC).

 

Speaker Bio
Christine Probst
Application Scientist
Merck KGaA, Darmstadt, Germany
Christine Probst holds her master’s and bachelor’s degrees in bioengineering. She currently works as an application scientist at Merck where she develops new assays using Amnis® imaging flow cytometry. For the past 4 years, her primary focus has been analysis of sub-visible particles in therapeutic protein and vaccines using imaging flow cytometry. In this presentation, Christine will discuss how imaging flow cytometry addresses limitations of current particle analysis techniques, and will present several case studies where imaging flow cytometry yielded new insights into therapeutic formulations.